CN104854099B - 非马沙坦钾盐的一水合物晶体、其制备方法及包含其的药物组合物 - Google Patents

非马沙坦钾盐的一水合物晶体、其制备方法及包含其的药物组合物 Download PDF

Info

Publication number
CN104854099B
CN104854099B CN201380063465.5A CN201380063465A CN104854099B CN 104854099 B CN104854099 B CN 104854099B CN 201380063465 A CN201380063465 A CN 201380063465A CN 104854099 B CN104854099 B CN 104854099B
Authority
CN
China
Prior art keywords
potassium salt
fimasartan potassium
fimasartan
monohydrate
salt monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380063465.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104854099A (zh
Inventor
金济学
金知汉
李濬光
柳炳旭
韩南锡
南京完
金昶模
李柱翰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boryung Pharmaceutical Co Ltd
Original Assignee
Boryung Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boryung Pharmaceutical Co Ltd filed Critical Boryung Pharmaceutical Co Ltd
Publication of CN104854099A publication Critical patent/CN104854099A/zh
Application granted granted Critical
Publication of CN104854099B publication Critical patent/CN104854099B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380063465.5A 2012-10-12 2013-10-11 非马沙坦钾盐的一水合物晶体、其制备方法及包含其的药物组合物 Expired - Fee Related CN104854099B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120113848A KR101490329B1 (ko) 2012-10-12 2012-10-12 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
KR10-2012-0113848 2012-10-12
PCT/KR2013/009097 WO2014058268A1 (ko) 2012-10-12 2013-10-11 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물

Publications (2)

Publication Number Publication Date
CN104854099A CN104854099A (zh) 2015-08-19
CN104854099B true CN104854099B (zh) 2016-11-16

Family

ID=50477658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380063465.5A Expired - Fee Related CN104854099B (zh) 2012-10-12 2013-10-11 非马沙坦钾盐的一水合物晶体、其制备方法及包含其的药物组合物

Country Status (13)

Country Link
EP (1) EP2927226A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101490329B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104854099B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013330603B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015008170A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2887056C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN03975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX353635B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY169064A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015500794A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2613555C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA515360275B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014058268A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102247408B1 (ko) 2017-09-18 2021-05-03 보령제약 주식회사 피마살탄 프로드러그
KR102402501B1 (ko) * 2018-04-24 2022-05-26 (주)국전약품 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물
KR102221856B1 (ko) 2020-10-12 2021-03-02 유니셀랩 주식회사 신규한 피마살탄 결정형의 다형체
KR20230062916A (ko) 2021-11-01 2023-05-09 그린케미칼 주식회사 피마살탄 무수물 a형 결정다형 및 그 제조방법
KR20230062917A (ko) 2021-11-01 2023-05-09 그린케미칼 주식회사 피마살탄 일수화물 b형 결정다형 및 그 제조방법
KR20240146734A (ko) 2023-03-30 2024-10-08 (주) 에프엔지리서치 피마살탄의 신규 염 및 이의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160395A (zh) * 1994-09-17 1997-09-24 保宁制药株式会社 嘧啶酮衍生物
CN1266428A (zh) * 1998-04-25 2000-09-13 保宁制药株式会社 嘧啶酮化合物,包含该化合物的药物组合物以及制备该化合物的方法
KR20010090193A (ko) * 2000-03-23 2001-10-18 조생현 피리미디논 화합물 및 이의 염의 제조방법
KR20040032639A (ko) * 2002-10-10 2004-04-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
CN1558906A (zh) * 2001-09-21 2004-12-29 保宁制药株式会社 嘧啶酮化合物及其药学上可接受的盐的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141385A1 (en) * 2011-04-12 2012-10-18 Boryung Pharmaceutical Co., Ltd. Antihypertensive pharmaceutical composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160395A (zh) * 1994-09-17 1997-09-24 保宁制药株式会社 嘧啶酮衍生物
CN1266428A (zh) * 1998-04-25 2000-09-13 保宁制药株式会社 嘧啶酮化合物,包含该化合物的药物组合物以及制备该化合物的方法
KR20010090193A (ko) * 2000-03-23 2001-10-18 조생현 피리미디논 화합물 및 이의 염의 제조방법
CN1558906A (zh) * 2001-09-21 2004-12-29 保宁制药株式会社 嘧啶酮化合物及其药学上可接受的盐的制备方法
KR20040032639A (ko) * 2002-10-10 2004-04-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법

Also Published As

Publication number Publication date
KR101490329B1 (ko) 2015-02-04
SA515360275B1 (ar) 2017-07-11
MX353635B (es) 2018-01-22
MX2015004573A (es) 2015-07-21
WO2014058268A1 (ko) 2014-04-17
CN104854099A (zh) 2015-08-19
AU2013330603A1 (en) 2015-05-28
IN2015DN03975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-10-02
CA2887056C (en) 2017-09-05
MY169064A (en) 2019-02-12
CA2887056A1 (en) 2014-04-17
BR112015008170A2 (pt) 2017-07-04
AU2013330603B2 (en) 2016-03-31
RU2015117524A (ru) 2016-12-10
KR20140047483A (ko) 2014-04-22
PH12015500794A1 (en) 2015-06-15
EP2927226A4 (en) 2016-07-13
RU2613555C2 (ru) 2017-03-17
EP2927226A1 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
CN104854099B (zh) 非马沙坦钾盐的一水合物晶体、其制备方法及包含其的药物组合物
CN105121434B (zh) 坎格列净一水合物及其晶型、它们的制备方法和用途
JP5134552B2 (ja) ジヒドロプテリジノン誘導体の三塩酸塩形及び調製方法
KR20180032680A (ko) 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
CN112142679B (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
US9073899B2 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
CN104284897B (zh) 替卡格雷晶型及其制备方法和用途
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN107849007B (zh) 比拉斯汀的晶型及其制备方法
WO2016155578A1 (zh) 达格列净的新晶型及其制备方法
WO2018010622A1 (zh) 化合物的晶型及其制备方法、组合物和应用
US20160046615A1 (en) Novel Crystal Form of Dabrafenib Mesylate and Preparation Method Thereof
WO2017162139A1 (zh) 用于治疗或预防jak相关疾病药物的盐酸盐晶型及其制备方法
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN104936947B (zh) 氯卡色林盐及其晶体、其制备方法和用途
JP6491653B2 (ja) アルコール消費を低減するためまたは過剰のアルコール消費を防止するための薬剤としてのナルメフェン塩
US20060293375A1 (en) Crystal of benzimidazole derivative and process for producing the same
WO2025169150A1 (en) Crystalline forms, crystalline salt forms, compositions containing the same, and methods of using the same
CN105308043B (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2017152846A1 (zh) 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
JP7671362B2 (ja) 医薬組成物、その製造方法及び使用
CN113277980B (zh) 托伐普坦杂质及其制备方法
WO2015107545A1 (en) Water soluble salts of dasatinib hydrate
HK40079891A (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161116